POSTER: CT-107 Cost-Effectiveness of the Chimeric Antigen Receptor (CAR) T-Cell Treatments, Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axicel), as Second-Line (2L) Treatment of Large B-Cell Lymphoma (LBCL)
Articles > Article ยท 2023
Authors: Matthew Lunning, Kristen A. Deger, Fei Fei Liu, Ahmed Elsada, Sven L. Klijn, Michal Litkiewicz, Conrado Franco-Villalobos, Sonja V. Sorensen
Clinical Lymphoma Myeloma and Leukemia, International, WoS, 2023, vol 23, pp S228-S228